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Abstract: A new series of morpholinyl-chalcones 2a–d was prepared by reaction of 2-oxo-N,4-diarylbut-3-enehydrazonoyl chlorides 1a–d with 
morpholine. These chalcones were used as a building block for constructing pyrazoles 3a–d and 3,4-dihydropyrimidine-2(1H)-thione 6 via their 
reaction with phenylhydrazine and thiourea, respectively. Moreover, a new series of azolopyrimidine derivatives 11a,b, 15, 17, 19, and 21 
incorporating morpholine moiety were synthesized by reaction of 1-morpholino-4-phenyl-1-(2-phenylhydrazono)but-3-en-2-one (2a) with a 
number of heterocyclic amines in the presence of a catalytic amount of acetic acid. The assigned structures for all the newly synthesized 
compounds were confirmed on the basis of elemental analyses and spectral data and the mechanisms of their formation were also discussed. 
All the synthesized compounds were tested for in vitro activities against two antitumor cell lines, human lung cancer (A-549) and human 
hepatocellular carcinoma (HepG-2) compared with the employed standard antitumor drug (cisplatin) and the results revealed that compounds 
6, 8c and 17 have promising activities compared with cisplatin. 
 





YDRAZONOYL halides are compounds which have the 
characteristic functionality –C(X):NNH–, where X is a 
halogen (Br or Cl). An increasing flow of work has appeared 
on the chemistry of such a class of compounds. They have 
recently reawaken interest in their chemistry as they 
proved to be useful building blocks for one-pot synthesis of 





nones[17] and benzopyranotriazepines.[18] Literature reveals 
that morpholine derivatives have found great significance 
in modern years due to their variety of pharmacological 
activities including anticancer, anti-inflammatory, analge-
sic, antidepressant, antifungal, anti-parasitic, antiplatelet, 
anti-tuberculosis, HIV-protease inhibitors, selective inhibi-
tor of protein kinase C, neuroprotective and anti-malar-
ial.[19–23] In addition, many pyrimidines and triazolo-
pyrimidines are pharmacological scaffolds displaying a wide 
range of biological activities such as anticancer, anti-
microbial, hypoglycemic, CNS depressant, antiallergy, anti-
inflammatory, and diuretic activities.[24–33] On the other 
hand, pyrazoles have been reported to possess a variety of 
significant and diverse pharmacological activities such as 
antibacterial, antifungal, anticonvulsant, antiviral, anti-
tubercular, antidepressant, anti-inflammatory, antiamoebic, 
analgesic and anticancer activity.[34–39] In view of all these 
reports and in continuation of our previous work in 
synthesis of bioactive heterocyclic compounds,[40–47] 
herein, we are interested in synthesizing a new series of 
pyrazoles and azolopyrimidines using morpholinylchal-
cones as common precursor and evaluate these com-
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Melting points were measured on an Electrothermal IA 
9000 series digital melting point apparatus. IR spectra were 
recorded in potassium bromide discs on Pye Unicam SP 
3300 and Shimadzu FTIR 8101 PC infrared spectrophotom-
eters. The 1H and 13C NMR spectra were recorded on a 
Varian 6 Mercury VX-300 NMR spectrometer (Karlsruhe, 
Germany). 1H NMR (300 MHz) and 13C NMR (75 MHz) were 
run in DMSO-d6 and chemical shifts are expressed in ppm 
units using TMS as an internal reference. Mass spectra were 
recorded on a Shimadzu GCMS-QP1000 EX mass spectrom-
eter at 70 eV. Elemental analyses were measured by using 
a German made Elementar vario LIII CHNS analyzer. 
Antitumor activity was evaluated at the Regional Center for 
Mycology and Biotechnology at Al-Azhar University, Cairo, 
Egypt. 
Synthesis of Pyrazoles 3a–d 
A mixture of chalcones 2a–d (1 mmol) and phenylhydrazine 
(0.108 g, 1 mmol) in 15 mL of ethanol containing 1 mL of 
glacial acetic acid was refluxed for 4–10 h (monitored 
through TLC). The desired product precipitated from 
reaction mixture was filtered, washed with ethanol and 
recrystallized from proper solvent to give the respective 




Orange solid, (70 % yield), mp 188–190 °C (EtOH); IR (KBr) 
νmax 1595 (C=N), 1663 (C=O), 3036, 2927 (C–H), 3263, 3429 
(2NH) cm–1; 1H NMR (DMSO-d6) δ 6.67–7.13 (m, 10H, Ar–H), 
7.20 (s, 1H, pyrazole-H4), 7.29–7.50 (m, 5H, Ar–H), 9.78 
(brs, 1H, NH), 10.87 (brs, 1H, NH); MS m / z (%) 354 (M+, 2), 
293 (4), 178 (17), 148 (5), 118 (12), 92 (46), 77 (54), 69 (42), 
65 (30), 43 (100). Anal. Calcd. for C22H18N4O (354.41): C, 




Orange solid, (60 % yield), mp 203–205 °C (EtOH); IR (KBr) 
νmax 1597 (C=N), 1671 (C=O), 3050, 2928 (C-H), 3263, 3420 
(2NH) cm–1; 1H NMR (DMSO-d6) δ 2.35 (s, 3H, CH3), 6.68–
7.16 (m, 10H, Ar–H), 7.24 (s, 1H, pyrazole-H4), 7.31-7.76 (m, 
4H, Ar–H), 9.58 (brs, 1H, NH), 9.81 (brs, 1H, NH); 13C-NMR 
(DMSO-d6): δ 21.1 (CH3), 112.3, 120.3, 121.0, 121.9, 123.5, 
126.1, 126.9, 127.4, 127.9, 128.2, 130.5, 132.7, 133.9, 
139.4, 149.7 (Ar–C and C=N), 168.7 (C=O); MS m / z (%) 368 
(M+, 7), 321 (9), 291 (3), 275 (4), 233 (4), 208 (5), 178 (3), 
119 (40), 106 (45), 91 (100), 77 (37), 43 (75). Anal. Calcd. for 
C23H20N4O (368.44): C, 74.98; H, 5.47; N, 15.21. Found: C, 




Orange solid, (60 % yield), mp 206–208 °C (Dioxane); IR 
(KBr) νmax 1596 (C=N), 1672 (C=O), 3032, 3102 (C–H), 
3251, 3280 (2NH) cm–1; 1H NMR (DMSO-d6) δ 2.35 (s, 3H, 
CH3), 6.68–7.24 (m, 10H, Ar–H), 7.89 (s, 1H, pyrazole-H4), 
7.38–7.89 (m, 4H, Ar–H), 9.61 (brs, 1H, NH), 9.83 (brs, 1H, 
NH); MS m / z (%) 390 (M++2, 2), 388 (M+, 7), 313 (3), 262 
(3), 210 (4), 165 (4), 139 (24), 106 (27), 91 (36), 77 (42),  
57 (62), 43 (100). Anal. Calcd. for C22H17ClN4O (388.86):  





Orange solid, (60 % yield), mp 212–214 °C (Dioxane); IR 
(KBr) νmax 1598 (C=N), 1648 (C=O), 3025 (C–H), 3283, 3236 
(2NH) cm–1; 1H NMR (DMSO-d6) δ 1.89 (s, 3H, CH3), 6.66–
7.19 (m, 9H, Ar–H), 7.39 (s, 1H, pyrazole-H4), 7.58–7.93 (m, 
4H, Ar–H), 9.58 (brs, 1H, NH), 9.88 (brs, 1H, NH); 13C-NMR 
(DMSO-d6): δ 20.4 (CH3), 111.6, 112.0, 118.2, 120.5, 121.3, 
124.6, 126.2, 126.8, 128.4, 128.8, 130.4, 133.5, 135.9, 
149.2, 168.8 (Ar–C and C=N), 168.0 (C=O); MS m / z (%) 404 
(M++2, 2), 402 (M+, 8), 427 (4), 404 (4), 368 (9), 336 (6), 300 
(5), 270 (9), 238 (7), 199 (9), 168 (11), 143 (37), 114 (30), 68 
(42), 55 (37), 43 (100). Anal. Calcd. for C23H19N4OCl (402.88): 
C, 68.57; H, 4.75; N, 13.91. Found: C, 68.50; H, 4.90; N, 
13.65 %. 
 
SYNTHESIS OF 6-(MORPHOLINO- 
(2-PHENYLHYDRAZONO)METHYL)-4-PHENYL- 
3,4-DIHYDROPYRIMIDINE-2(1H)-THIONE (6) 
A mixture of 1-morpholino-4-phenyl-1-(2-phenylhydra-
zono)but-3-en-2-one (2a) (3.35 g, 10 mmol) and thiourea 
(0.76 g, 10 mmol) in 40 mL of ethanol containing catalytic 
amount of potassium hydroxide was refluxed for 6 h 
(monitored through TLC). The reaction mixture was then 
poured into 2 N HCl, and the solid product was collected 
by filtration followed by washing with water and EtOH. 
The crude product was recrystallized from DMF to give 
pure product of compound 6 as yellowish-white solid  
in 75 % yield, mp 190–193°C; IR (KBr) νmax 1598 (C=N), 
2927, 3054 (C–H), 3165, 3249, 3425 (3NH) cm–1; 1H NMR 
(DMSO-d6) δ 2.37–2.40 (m, 4H, 2CH2), 3.41–3.45 (m,  
4H, 2CH2), 4.63 (d, J = 4.1 Hz, 1H, pyrimidine-H6), 6.60  
(d, J = 4.1 Hz, 1H, pyrimidine-H5), 7.14–7.52 (m, 10H,  
Ar–H), 9.63 (brs, 1H, NH), 10.17 (brs, 1H, NH), 11.13 (brs, 
1H, 1NH); MS m / z (%) 393 (M+, 100), 368 (37), 353 (40), 
320 (38), 295 (38), 247 (4), 194 (4), 118 (10), 76 (49),  
65 (23), 42 (31). Anal. Calcd. for C21H23N5OS (393.51):  
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Triethylamine (0.14 mL, 1 mmol) was added to a mixture of 
equimolar amounts of thione 6 (0.393 g, 1 mmol) and the 
appropriate hydrazonoyl halides 7a–d (1 mmol) in dioxane 
(20 mL) at room temperature. The reaction mixture was 
refluxed till all of the starting materials have been 
disappeared and hydrogen sulfide gas ceased to evolve (6–
10 h, monitored by TLC). The solvent was evaporated and 
the residue was triturated with methanol. The solid that 
formed was filtered and recrystallized from the proper 





Green solid, (70 % yield), mp 219–221 °C (Dioxane); IR (KBr) 
νmax 1599 (C=N), 1650 (C=O), 3024, 2957 (C–H), 3253 (NH) 
cm–1; 1H NMR (DMSO-d6) δ 2.33–2.37 (m, 4H, 2CH2), 2.45 
(s, 3H, CH3), 3.44–3.46 (m, 4H, 2CH2), 4.67 (d, J = 4.1 Hz, 1H, 
pyrimidine-H5), 6.69 (d, J = 4.1 Hz, 1H, pyrimidine-H6), 
7.12–7.61 (m, 15H, Ar–H), 11.20 (brs, 1H, NH); 13C-NMR 
(DMSO-d6): δ 24.1 (CH3), 50.1 (CH), 54.0, 65.6 (CH2), 113.7, 
117.3, 121.2, 122.0, 122.6, 123.3, 124.8, 126.3, 128.2, 
128.9, 129.1, 130.2, 132.7, 133.0, 136.2, 139.7, 151.4 (Ar–C 
and C=N), 193.8 (C=O); MS m / z (%) 519 (M+, 7), 491 (11), 
458 (10), 372 (18), 355 (14), 321 (54), 293 (100), 249 (16), 
54 (38). Anal. Calcd. for C30H29N7O2 (519.61): C, 69.35; H, 





Green solid, (75 % yield), mp 213-215 °C (EtOH); IR (KBr) 
νmax 1597 (C=N), 1676 (C=O), 2976, 3032 (C–H), 3250 (NH) 
cm–1; 1H NMR (DMSO-d6) δ 2.30–2.33 (m, 4H, 2CH2), 2.28 
(s, 3H, CH3), 2.44 (s, 3H, CH3), 3.53–3.56 (m, 4H, 2CH2), 4.63 
(d, J = 4.1 Hz, 1H, pyrimidine-H5), 6.67 (d, J = 4.1 Hz, 1H, 
pyrimidine-H6), 7.07–7.63 (m, 14H, Ar–H), 11.12 (brs, 1H, 
NH); MS m / z (%) 533 (M+, 4), 439 (19), 416 (12), 393 (12), 
360 (12), 353 (18), 77 (22), 65 (44), 51 (81), 43 (100). Anal. 
Calcd. for C31H31N7O2 (533.64): C, 69.77; H, 5.86; N, 18.37. 





Green solid, (70 % yield), mp 235–237 °C (DMF); IR (KBr) νmax 
1599 (C=N), 1735 (C=O), 2916, 2962 (C-H), 3250 (NH) cm–1; 
1H NMR (DMSO-d6) δ 1.15 (t, J = 7.2 Hz, 3H, CH3), 2.41–2.44 
(m, 4H, 2CH2), 3.30–3.32 (m, 4H, 2CH2), 4.18 (q, J = 7.2 Hz, 
2H, CH2), 4.47 (d, J = 4.1 Hz, 1H, pyrimidine-H5), 6.72 (d, J = 
4.1 Hz, 1H, pyrimidine-H6), 7.00–7.81 (m, 15H, Ar–H), 10.80 
(brs, 1H, NH); 13C-NMR (DMSO-d6): δ 14.8 (CH3), 50.2 (CH), 
54.0, 60.8, 66.2 (CH2), 114.8, 116.3, 120.3, 120.4, 120.3, 
122.3, 123.3, 124.5, 124.9, 126.8, 128.7, 128.8, 129.2, 
129.3, 129.4, 140.9, 152.5 (Ar-C and C=N), 166.7 (C=O); MS 
m / z (%) 549 (M+, 8), 488 (27), 455 (24), 421 (9), 405 (12), 
384 (40), 368 (96), 323 (25), 135 (39), 75 (100). Anal. Calcd. 
for C31H31N7O3 (549.63): C, 67.74; H, 5.69; N, 17.84. Found: 





Green solid, (74 % yield), mp 201–203 °C (EtOH); IR (KBr) 
νmax 1593 (C=N), 1740 (C=O), 2918 (C-H), 3432 (NH) cm–1; 1H 
NMR (DMSO-d6) δ 1.16–1.21 (t, J = 7.2 Hz, 3H, CH2CH3), 
2.34–2.37 (m, 4H, 2CH2), 2.30 (s, 3H, CH3), 3.42–3.46  
(m, 4H, 2CH2), 4.20 (q, J = 7.2 Hz, 2H, CH2CH3), 4.80 (d, J = 
4.1 Hz, 1H, pyrimidine-H5), 6.89 (d, J = 4.1 Hz, 1H, 
pyrimidine-H6), 7.50–8.06 (m, 14H, Ar–H), 11.20 (brs, 1H, 
NH); MS m / z (%) 563 (M+, 1), 499 (16), 447 (11), 422 (9), 
398 (30), 370 (17), 355 (67), 326 (17), 294 (34), 90 (11), 77 
(100), 50 (21). Anal. Calcd. for C32H33N7O3 (563.66):  
C, 68.19; H, 5.90; N, 17.39. Found: C, 68.50; H, 5.60; N, 
17.09 %. 
General Method for Synthesis of 
Compounds 11a,b, 15, 17, 19 and 21 
A mixture of each of 1-morpholino-4-phenyl-1-(2-
phenylhydrazono)but-3-en-2-one (2a) (0.335 g, 1 mmol) 
and the appropriate heterocyclic amine (9a,b, 14, 16, 18 or 
20) (1 mmol) in ethanol (20 mL) in the presence of catalytic 
drops of acetic acid was refluxed for 10–15 h (monitored 
through TLC). The reaction mixture was poured into water 
and the solid product was collected by filtration followed 
by washing with ethanol. The crude product was then 
recrystallized from DMF to give pure products of 11a,b, 15, 
17, 19 and 21, respectively. Compounds 11a,b, 15, 17, 19 
and 21 with their physical constants and spectral data are 




Yellow solid, (70 % yield), mp 219–220 °C; IR (KBr) νmax 1600 
(C=N), 2950, 3055 (C-H), 3247 (NH) cm–1; 1H NMR (DMSO-
d6) δ 2.32–2.34 (m, 4H, 2CH2), 3.80–3.83 (m, 4H, 2CH2), 
7.00–7.46 (m, 10H, Ar-H), 8.01 (s, 1H, triazole-H3), 8.19 (s, 
1H, pyrimidine-H5), 10.65 (brs, 1H, NH); 13C-NMR (DMSO-
d6): δ 51.7, 61.4 (CH2), 115.2, 117.0, 119.2, 121.5, 122.0, 
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(Ar–C and C=N); MS m / z (%) 399 (M+, 15), 386 (16), 365 
(27), 357 (22), 322 (20), 293 (38), 278 (16), 104 (27), 77 (42), 
56 (48), 43 (100), 41 (58). Anal. Calcd. for C22H21N7O 
(399.18): C, 66.15; H, 5.30; N, 24.55. Found: C, 65.93; H, 




Yellow solid, (72 % yield), mp 233-235 °C; IR (KBr) νmax 1600 
(C=N), 2950, 3018 (C–H), 3245 (NH) cm–1; 1H NMR (DMSO-
d6) δ 2.32–2.34 (m, 4H, 2CH2), 3.82-3.85 (m, 4H, 
2CH2),  7.02–7.49 (m, 10H, Ar–H), 8.09 (s, 1H, pyrimidine-
H5), 10.65 (brs, 1H, NH); MS m / z (%) 400 (M+, 31), 395 (42), 
366 (65), 335 (58), 322 (56), 96 (31), 88 (46), 60 (100). Anal. 
Calcd. for C21H20N8O (400.18): C, 62.99; H, 5.03; N, 27.98. 




Yellow solid, (75 % yield), mp 255–257 °C; IR (KBr) νmax 1600 
(C=N), 2948, 3019 (C–H), 3246 (NH) cm–1; 1H NMR (DMSO-
d6) δ 2.30–2.32 (m, 4H, 2CH2), 3.71–3.73 (m, 4H, 
2CH2),  7.14–7.49 (m, 14H, Ar-H), 8.06 (s, 1H, pyrimidine-
H5), 10.82 (brs, 1H, NH); 13C-NMR (DMSO-d6): δ 53.2, 61.1 
(CH2), 115.7, 118.3, 120.1, 120.5, 122.3, 124.1, 124.8, 
126.9, 126.9,  129.4, 130.3, 130.8, 133.6, 134.5, 134.8, 
137.1, 139.2, 141.6, 159.6 (Ar–C and C=N); MS m / z (%) 448 
(M+, 21), 372 (32), 357 (100), 349 (56), 333 (56), 305 (64), 
294 (53), 264 (83), 217 (36), 200 (23), 159 (27), 110 (48), 74 
(82), 44 (82). Anal. Calcd. for C27H24N6O (448.20): C, 72.30; 





Yellow solid, (69 % yield), mp 225–227 °C; IR (KBr) νmax 1612 
(C=N), 2910, 2955 (C–H), 3417 (NH) cm–1; 1H NMR (DMSO-
d6) δ 2.30–2.32 (m, 4H, 2CH2), 3.69–3.72 (m, 4H, 2CH2), 2.34 
(s, 3H, CH3), 2.64 (s, 3H, CH3), 6.83 (s, 1H, pyridine-H), 6.97–
7.57 (m, 10H, Ar–H), 8.15 (s, 1H, pyrimidine-H5),10.67 (brs, 
1H, NH); MS m / z (%) 477 (M+, 6), 365 (20), 326 (23), 307 
(11), 270 (17), 208 (13), 166 (25), 147 (20), 91 (21), 69 (100). 
Anal. Calcd. for C28H27N7O (477.23): C, 70.42; H, 5.70; N, 




Yellow solid, (73 % yield), mp 219–221 °C; IR (KBr) νmax 1599 
(C=N), 2948, 3018 (C–H), 3246, (NH) cm–1; 1H NMR (DMSO-
d6) δ 2.01–2.22 (m, 4H, 2CH2), 3.72–3.75 (m, 4H, 2CH2), 4.45 
(1H, d, J = 4.6 Hz, pyrimidine-H), 6.59 (1H, d, J = 4.6 Hz, 
pyrimidine-H), 6.72–7.46 (m, 12H, Ar-H), 10.65 (brs, 1H, 
NH); MS m / z (%) 417 (M+, 7), 322 (100), 293 (52), 278 (16), 
252 (50), 246 (12), 144 (8), 76 (9), 42 (38). Anal. Calcd. for 
C23H23N5OS (417.53): C, 66.16; H, 5.55; N, 16.77. Found: C, 





Yellow solid, (80 % yield), mp 244–246 °C; IR (KBr) νmax 1599 
(C=N), 2948, 3017 (C–H), 3245 (NH) cm–1; 1H NMR (DMSO-
d6) δ 2.30–2.31(m, 4H, 2CH2), 3.70–3.71 (m, 4H, 2CH2), 4.48 
(1H, d, J = 4.6 Hz, pyrimidine-H), 6.52 (1H, d, J = 4.6 Hz, 
pyrimidine-H), 7.02–7.61 (m, 14H, Ar-H), 10.55 (brs, 1H, 
NH); MS m / z (%) 483 (M+, 10), 382 (25), 368 (19), 294 
(100), 267 (24), 155 (17), 92 (30), 76 (51), 43 (90). Anal. 
Calcd. for C27H25N5OS  (467.59): C, 69.35; H, 5.39; N, 14.98. 
Found: C, 69.30; H, 5.27; N, 14.73 %. 
Evaluation of Cytotoxic Effects of 
Compounds 
 
MAMMALIAN CELL LINES 
A-549 cells (human Lung cancer cell line, HepG-2 cells 
(human Hepatocellular carcinoma) were obtained from 
VACSERA Tissue Culture Unit.  
 
CHEMICALS USED 
Dimethyl sulfoxide (DMSO), crystal violet and trypan blue 
dye were purchased from Sigma (St. Louis, Mo., USA). 
 Fetal Bovine serum, DMEM, RPMI-1640, HEPES 
buffer solution, L-glutamine, gentamycin and 0.25 % 
Trypsin-EDTA were purchased from Lonza. 
 
CRYSTAL VIOLET STAIN (1 %) 
It composed of 0.5 % (w / v) crystal violet and 50 % 
methanol then made up to volume with ddH2O and filtered 
through a Whatmann No.1 filter paper. 
 
CELL LINE PROPAGATION 
The cells were propagated in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10 % heat-inactivated 
fetal bovine serum, 1 % L-glutamine, HEPES buffer and  
50 µg mL–1 gentamycin. All cells were maintained at 37 °C 
in a humidified atmosphere with 5 % CO2 and were 
subcultured two times a week. 
 
CYTOTOXICITY EVALUATION USING VIABILITY ASSAY 
For cytotoxicity assay, the cells were seeded in 96-well 
plate at a cell concentration of 1 × 104 cells per well in 100µl 
of growth medium. Fresh medium containing different 
concentrations of the test sample was added after 24 h of 
seeding. Serial two-fold dilutions of the tested chemical 
compound were added to confluent cell monolayers 
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(Falcon, NJ, USA) using a multichannel pipette. The 
microtiter plates were incubated at 37 °C in a humidified 
incubator with 5 % CO2 for a period of 48 h. Three wells 
were used for each concentration of the test sample. 
Control cells were incubated without test sample and with 
or without DMSO. The little percentage of DMSO present in 
the wells (maximal 0.1 %) was found not to affect the 
experiment. After incubation of the cells for at 37 °C, 
various concentrations of sample were added, and the 
incubation was continued for 24 h and viable cells yield was 
determined by a colorimetric method. 
 In brief, after the end of the incubation period, 
media were aspirated and the crystal violet solution (1 %) 
was added to each well for at least 30 minutes. The stain 
was removed and the plates were rinsed using tap water 
until all excess stain is removed. Glacial acetic acid (30 %) 
was then added to all wells and mixed thoroughly, and then 
the absorbance of the plates were measured after gently 
shaken on Microplate reader (TECAN, Inc.), using a test 
wavelength of 490 nm. All results were corrected for 
background absorbance detected in wells without added 
stain. Treated samples were compared with the cell control 
in the absence of the tested compounds. All experiments 
were carried out in triplicate. The cell cytotoxic effect of 
each tested compound was calculated. The optical density 
was measured with the microplate reader (SunRise, TECAN, 
Inc, USA) to determine the number of viable cells and the 
percentage of viability was calculated as [1-(ODt/ODc)] × 
100 % where ODt is the mean optical density of wells 
treated with the tested sample and ODc is the mean optical 
density of untreated cells. The relation between surviving 
cells and drug concentration is plotted to get the survival 
curve of each tumor cell line after treatment with the 
specified compound. The 50 % inhibitory concentration 
(IC50), the concentration required to cause toxic effects in 
50 % of intact cells, was estimated from graphic plots of the 
dose response curve for each conc. using Graphpad Prism 
software (San Diego, CA. USA).[48] 
 
RESULTS AND DISCUSSION 
As previously described,[49] compounds 1a–d reacted with 
morpholine in ethanol under reflux for 3–6 hrs to give the 
morpholinohydrazonobutenone derivatives 2a–d (Scheme 
1), which were used as a precursors for synthesis of 
pyrazoles, pyrimidines, and different fused pyrimidines, 
such as triazolopyrimidine, tetrazolopyrimidine, thiazolo–
pyrimidine, benzothiazolo-pyrimidine benzoimidazo–
pyrimidine, and pyridopyrazolopyrimidine derivatives. 
 Compounds 2a–d were refluxed in ethanol 
containing catalytic amount of acetic acid with 
phenylhydrazine for 4–10 hrs affording the corresponding 
pyrazole derivatives 3a–d, rather than the compounds 4a–d 
(Scheme 1), what was confirmed based on the mass 
spectrum and IR spectrum which showed a peak at 1715 
cm–1 that revealed the presence of amidic carbonyl group. 
All the spectral data and elemental analyses of these 
compounds were in agreement with the proposed 
structures (see Experiment).  
 On the other hand, morpholinohydrazinophenyl–
butenone derivative 2a was heated under reflux with 
thiourea (5) and gave the 6-(morpholino(2-phenyl–
hydrazono)methyl)-4-phenyl-3,4-dihydropyrimidine-2(1H)-
thione (6) (Scheme 2). 
 Furthermore, compound 6 with hydrazonoyl 
chlorides 7a–d afforded the corresponding sulphur free 
compounds pyridotriazolopyrimidine 8a–d (Scheme 2). IR 
spectrum for 1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidinone 
derivative 8a, as an example, gave peaks at 1650 and  
3253 cm–1 that correspond to C=O and NH groups. Its  
1H-NMR spectrum revealed the presence of only one NH 
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compounds 8a–d were confirmed by spectral data and 
elemental analyses (see Experimental). 
 Compound 2a was then used for preparation of 
azolopyrimidine compounds via its reactions with a variety 
of heterocyclic amines. For example, reaction of each of 
compound 2a with 5-amino-1,2,4-triazole 9a or 5-amino-
1,2,3,4-tetrazole 9b in the presence of a catalytic amount 
of acetic acid under reflux afforded triazolo[1,5-
a]pyrimidine derivative 11a and tetrazolo[1,5-a]pyrimidine 
derivative 11b, respectively (Scheme 3). The structure 
assigned to these products was confirmed based on 
elemental analysis and spectroscopic methods (IR, 1H NMR 
and mass spectra) (see Experimental). For example, the IR 
spectra of products 11a revealed an absorption band at υ = 
3247 due to hydrazine-NH group. Its 1H NMR (DMSO-d6) 
showed signals at δ = 2.32–2.34 (m, 4H, 2CH2), 3.80–3.83 
(m, 4H, 2CH2), 7.00–7.46 (m, 10H, Ar-H), 8.01 (s, 1H, 
triazole-H3), 8.19 (s, 1H, pyrimidine-H5), 10.65 (brs, 1H,  
NH) ppm. The mass spectra of products 11a,b revealed a 
molecular ion peak for each one which is consistent with 
the respective molecular weight.  
 The suggested mechanism for the formation of 
compounds 11a,b was outlined in Scheme 3. It was 
postulated that the reaction of chalcone 2 with the 
appropriate heterocyclic amine starts with Michael 
addition (route a) of the amino group to the double bond 
of the enone residue of 2a to give intermediate 10 which 
undergoes in situ dehydrative cyclization followed by auto-
oxidation to give the final azolopyrimidine 11a,b. The 
spectral data and elemental analyses data are consistent 
with the regioisomeric structures 11 and 13. The isomeric 
compounds 13 produced by route b were discarded due to 
difficultness in condensation reaction than Michael 
addition (route a).[50,51] 
 However, an equimolar amount of compound 2a and 
2-aminobenzoimidazole 14 were heated under reflux in 
ethanol containing a catalytic amount of acetic acid to  
give benzo[4,5]imidazo[1,2-a]pyrimidine derivative 15 
(Scheme 4).  
 Similarly, compound 2a reacted with 
pyrazolopyridine amine derivative 16 and yielded 2-
phenylpyrido[2',3':3,4]pyrazolo[1,5-a]pyrimidine derivative 
17 (Scheme 4).  
 Finally, compound 2a was heated under reflux with 
2-aminothiazole 16 and 2-aminobenzothiazole 20 to afford 
thiazolo[3,2-a]pyrimidine 19 and benzo[4,5]thiazolo[3,2-
a]pyrimidine derivatives 21, respectively (Scheme 4). All 
spectral data and elemental analyses were in agreement 
with the proposed structures of compounds 15, 17, 19 and 
21 (see Experimental). 
Cytotoxic Activity 
The in vitro growth inhibitory activity of the newly 
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21 was investigated against two carcinoma cell lines, 
human lung cancer cell line (A-549) and human 
hepatocellular carcinoma cell line (HepG-2), in comparison 
with the well-known anticancer standard drug (cisplatin) 
under the same conditions using colorimetric MTT assay. 
Data generated were used to plot a dose response curve of 
which the concentration of test compounds required to kill 
50 % of cell population (IC50) was determined. The results 
are depicted in Table 1 and revealed that the descending 
order of activity of the newly synthesized compounds 
towards the lung carcinoma cell line (A549) were as 
follow: 6 > 8c > 17 > 11a > 21 > 15 > 11b > 8d > 3a > 19 > 
8b > 8a. 
 The descending order of activity of the newly 
synthesized compounds towards the human Hepatocellular 
carcinoma cell line (HepG-2) were as follow: 6 > 8c > 17 > 
11a > 21 > 15 > 8d > 11b > 19 > 3a > 8b > 8a. 
Structure Activity Relationship (SAR) 
Examination of the SAR leads to the following conclusions. 
 The results revealed that all the tested compounds 
showed inhibitory activity to the tumor cell lines in a 
concentration dependent manner. 
 The activities of the synthesized compounds depend 
on the structural skeleton and electronic environment of 
the molecules.  
 Compounds 6 and 8c were the most active (IC50 value 
of 2.81 ± 0.9, 3.45 ± 5.6 μg mL–1, respectively) against the 
lung carcinoma cell line (A549), compared with cisplatin 
reference drug with IC50 value of 0.95±0.9 μg mL–1. On the 
other hand, compounds 8a, 8b, 8d, 3a and 11b have poor 
inhibitory activity (IC50 > 30 µg mL–1) (Figure 1). 
 Compounds 6 and 17 were the most active (IC50 
value of 2.99 ± 1.8, 5.69 ± 9.8 μg mL–1, respectively) against 
the human hepatocellular carcinoma cell line (HepG-2), 
compared with cisplatin reference drug with IC50 value of 
1.40 ± 1.1 μg mL–1. On the other hand, compounds 8a, 8b 
and 3a have poor inhibitory activity (IC50 > 30 µg mL–1) 
(Figure 1). 
 Among the fused pyrimidine derivatives, 
triazolopyrimidine 11a is the most active one against the 
A549 (IC50 = 7.45 ± 0.7 μg mL–1) while the pyridopyrazolo–
pyrimidine 17 is the most active one against the HepG-2 cell 
line (A549) (IC50 = 7.45 ± 0.7 μg mL–1).  
 For triazolopyrimidine derivatives 8a–d: compound 
8c (substituted with COOEt group at position 3) has in vitro 
inhibitory activity more than 8a (substituted with COCH3 
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In this context, a new series of morpholinyl-chalcones was 
prepared and used as a building block for constructing 
pyrazoles, 3,4-dihydropyrimidine-2(1H)-thione and azolo–
pyrimidines via their reaction with phenylhydrazine 
thiourea and a number of heterocyclic amines, respec-
tively. The assigned structures for all the newly synthesized 
compounds were confirmed on the basis of elemental anal-
yses and spectral data and the mechanisms of their 
formation were also discussed. Some of the synthesized 
compounds were tested for in vitro activities against the 
human lung cancer cell lines (A-549) and human hepatocel-
lular carcinoma cell lines (HepG-2) and the results revealed 
that compounds 6, 8c and 17 have promising activities 
compared with cisplatin. Also, the SAR was studied. 
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